Ganciclovir

Lymphoma

National Cancer Institute (NCI)Small moleculePhase 2Dormant

B

61/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 58/ 100
Competitive Position: 65/ 100

Competitive context

288 Active assets in the Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Vinblastine Intensity Therapeutics, Inc.	Phase 4	BBB
Prednisolone The Lymphoma Academic Research Organisation	Phase 4	BBB
Cyclophosphamide Beth Israel Deaconess Medical Center	Phase 4	BB
Vincristine Sulfate Inhye Ahn	Phase 3	BB
Bleomycin Shandong Provincial Hospital	Phase 4	BB

View all 50 →

Same molecule, other indications

Ganciclovir is also rated in:

cytomegalovirus retinitisDormant

A

Indicative · Phase 4

82 / 100

HIV infectious diseaseDormant

BBB

Indicative · Phase 4

76 / 100

cytomegalovirus infectionActive

BB

Indicative · Phase 3

67 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.